Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

Cyclophosphamide 32fludarabine phosphate 25Peripheral Blood Stem Cell Transplantation 25Busulfan 20Antilymphocyte Serum 19Tacrolimus 15Mycophenolic Acid 15Filgrastim 15Cyclosporine 15Methotrexate 14Melphalan 12Etoposide 12pembrolizumab 11Whole-Body Irradiation 10Radiotherapy 10Methylprednisolone 10Sirolimus 9Psychiatric Rehabilitation 8Nivolumab 8Bortezomib 8fludarabine 7Prednisone 7Flow Cytometry 7sargramostim 6romidepsin 6Vorinostat 6Gemcitabine 6Doxorubicin 6Cord Blood Stem Cell Transplantation 6aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × siplizumab × Dermatologic × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡